Bruce K. Crowther Sells 20,734 Shares of NeoGenomics, Inc. (NASDAQ:NEO) Stock

Thursday, June 10, 2021 | MarketBeat

NeoGenomics, Inc. (NASDAQ:NEO) Director Bruce K. Crowther sold 20,734 shares of the firm's stock in a transaction that occurred on Tuesday, June 8th. The stock was sold at an average price of $41.46, for a total transaction of $859,631.64. Following the completion of the transaction, the director now directly owns 59,564 shares in the company, valued at $2,469,523.44. The transaction was disclosed in a document filed with the SEC, which is available through this link.

NASDAQ NEO traded up $0.27 on Thursday, reaching $42.87. The stock had a trading volume of 388,479 shares, compared to its average volume of 918,972. The company has a market capitalization of $5.06 billion, a price-to-earnings ratio of -531.63 and a beta of 0.69. The company has a quick ratio of 13.60, a current ratio of 13.91 and a debt-to-equity ratio of 0.63. NeoGenomics, Inc. has a 12-month low of $25.67 and a 12-month high of $61.57. The company's fifty day moving average price is $44.28.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Wednesday, May 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.05). The firm had revenue of $115.30 million during the quarter, compared to analysts' expectations of $112.17 million. NeoGenomics had a negative net margin of 2.42% and a positive return on equity of 0.83%. The firm's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.07) EPS. On average, sell-side analysts expect that NeoGenomics, Inc. will post -0.33 earnings per share for the current year.

Several research firms have recently commented on NEO. Craig Hallum lifted their price target on shares of NeoGenomics from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, February 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $65.00 price target on shares of NeoGenomics in a research report on Friday, April 16th. The Goldman Sachs Group began coverage on shares of NeoGenomics in a research report on Thursday, June 3rd. They set a "buy" rating and a $55.00 price target on the stock. Raymond James reaffirmed a "market perform" rating on shares of NeoGenomics in a research report on Wednesday, March 3rd. Finally, Zacks Investment Research lowered shares of NeoGenomics from a "hold" rating to a "sell" rating in a research report on Wednesday, April 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. NeoGenomics presently has an average rating of "Buy" and a consensus price target of $50.46.

Large investors have recently bought and sold shares of the business. Bedel Financial Consulting Inc. acquired a new position in shares of NeoGenomics in the first quarter worth $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of NeoGenomics in the fourth quarter worth $47,000. KBC Group NV acquired a new position in shares of NeoGenomics in the fourth quarter worth $56,000. Capital Asset Advisory Services LLC acquired a new position in shares of NeoGenomics in the fourth quarter worth $60,000. Finally, Captrust Financial Advisors grew its stake in shares of NeoGenomics by 516.3% in the first quarter. Captrust Financial Advisors now owns 1,325 shares of the medical research company's stock worth $64,000 after acquiring an additional 1,110 shares in the last quarter. Institutional investors and hedge funds own 90.82% of the company's stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.

Featured Article: Net Asset Value

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Intrinsic Value and Stock Selection


7 Stocks to Support Your New Year’s Resolutions

After a year like 2020, many Americans figure that just getting to 2021 was enough. But for many people, the start of a new year still means making resolutions. And while many Americans are still waking up to Groundhog’s Day, there is hope that things will look dramatically different in September than they do right now.

Some of the most popular resolutions include losing weight, exercising more, or taking steps to get our life and/or business more organized. And many pure-play companies lean into these trends and are doing well.

As an alternative to this, you can also invest in companies that are not pure plays but can still benefit from consumers looking to start fresh. Owning these stocks helps you manage your risk. If the trend holds, you can ride the wave. On the other hand, if the wave turns into a ripple, the stocks have other catalysts to get them through.

In this special presentation, we’ll take a look at both of these categories. We’ve got several pure-play companies that let investors buy stocks in companies benefiting from these trends. We’ll also give you a few stocks that fall in the latter category.

These are stocks that you might buy at any time and for many reasons. However, they present excellent buys as the new year begins.

View the "7 Stocks to Support Your New Year’s Resolutions".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.